Tanziela Tanziela | Drug Delivery | Innovative Research Award

Innovative Research Award

Tanziela Tanziela
Shandong Xiehe University

Tanziela Tanziela
Affiliation Shandong Xiehe University
Country China
Scopus ID 57219011913
Documents 10
Citations 211
h-index 5
Subject Area Drug Delivery
Event World Cell Biologist Awards
ORCID 0000-0002-7991-9620

Tanziela Tanziela of Shandong Xiehe University is a researcher with a focus on drug delivery. The profile presents the supplied academic information in the context of scholarly output, citation activity, research specialization, and the broader objectives of the World Cell Biologist Awards. The Innovative Research Award recognizes research that demonstrates originality, methodological development, and meaningful potential to contribute to scientific knowledge.[1]

Abstract

Tanziela Tanziela is affiliated with Shandong Xiehe University and is identified in the supplied academic profile with a specialization in drug delivery. The reported research record comprises 10 documents, 211 citations, and an h-index of 5. These indicators provide a quantitative overview of scholarly activity and research visibility, while the subject-area designation places the work within a field concerned with the design, development, characterization, and application of systems for delivering therapeutic agents. The Innovative Research Award profile therefore considers both documented research activity and its relevance to scientific innovation.

Keywords

Innovative Research Award; Tanziela Tanziela; Drug Delivery; Drug Delivery Systems; Pharmaceutical Research; Research Innovation; World Cell Biologist Awards

Introduction

Drug delivery research addresses the challenge of transporting therapeutic compounds to appropriate biological sites while improving delivery efficiency, stability, controlled release, and therapeutic performance. Advances in this area may involve formulation science, biomaterials, nanotechnology, pharmacological approaches, and targeted delivery strategies. Scholarly evaluation commonly combines qualitative assessment of research contributions with bibliometric indicators such as publications and citations. Scopus provides author-level bibliographic and citation information that can be used as one source for evaluating scholarly visibility. [1]

Research Profile

The researcher profile supplied for this article identifies Tanziela Tanziela as affiliated with Shandong Xiehe University in China. The principal subject area is listed as Drug Delivery. The profile reports 10 documents, 211 citations, and an h-index of 5. These values should be interpreted as profile-level indicators that may change as databases are updated and new publications or citations are indexed. [1]

Research Contributions

The supplied subject classification places Tanziela Tanziela’s research within drug delivery, an interdisciplinary area that connects pharmaceutical science with biological and materials-based approaches. Research in this field may investigate how therapeutic compounds are formulated, transported, released, protected from degradation, or delivered to specific biological environments. The researcher profile can therefore be considered relevant to scientific work involving drug-delivery mechanisms and related biomedical applications. [2]

Publications

The supplied profile records 10 documents associated with the Scopus author identifier 57219011913. Because publication metadata, indexing status, citation counts, and author profiles can change over time, individual publication details should be verified against the relevant bibliographic database before formal use in a curriculum vitae, award dossier, or institutional record. [3]

Research Impact

The reported citation count of 211 and h-index of 5 indicate measurable scholarly attention to the indexed publication record. Citation indicators can assist in assessing research visibility, but they should be interpreted alongside publication context, field-specific citation practices, career stage, collaboration patterns, and the substantive significance of individual findings. [4]

Award Suitability

The Innovative Research Award is intended to recognize research activity characterized by originality, scientific relevance, and meaningful contribution to a defined area of research. Based on the supplied information, Tanziela Tanziela’s specialization in drug delivery and documented scholarly profile provide a reasonable basis for consideration within an innovation-oriented research recognition framework.

Bibliometric indicators should be treated as supporting evidence rather than as a substitute for peer assessment. The suitability of the researcher for a specific award should ultimately be determined through the applicable nomination, documentation, and review procedures of the World Cell Biologist Awards. [5]

Conclusion

Tanziela Tanziela, affiliated with Shandong Xiehe University, is presented in the supplied profile as a researcher specializing in drug delivery. The reported record of 10 documents, 211 citations, and an h-index of 5 provides a concise quantitative description of scholarly activity and visibility. These indicators, together with the stated research specialization, support consideration within an innovative research recognition context, while a comprehensive award assessment should incorporate direct evaluation of publications, originality, methodological quality, and broader scientific contribution.

References

  1. Elsevier. (n.d.). Scopus author details: Tanziela Tanziela, Author ID 57219011913. Scopus.
    https://www.scopus.com/pages/authors/57219011913
  2. S Li, JX He, Z Zhou, YH Luo, J Zhuang, T Tanziela, et al. (2026). Repurposing Pentacyclic Triterpenoids as Ferroptosis Inducing Agents for Cancer Therapies.
    https://link.springer.com/article/10.1007/s40495-026-00453-2
  3. MI Ahmad, T Tanziela, MZ Ahmad, et al. (2025). Unraveling the contribution of GASA gene family in sunflower under diverse stress conditions.
    https://link.springer.com/article/10.1007/s11033-025-11028-7
  4. JX He, L Li, S Chen, RJ Chen, T Tanziela, et al. (2026). Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence.
    https://journals.sagepub.com/doi/abs/10.1177/15330338261440434
  5. M Nawaz, A Nawaz, MN Khan, T Tanziela, et al. (2025). Flavonoids being chemo‐preventive agents induce programmed cell death: mechanisms and therapeutic potentials.
    https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.70018

Amir Zarebkohan | Nanomedicine | Best Researcher Award

Dr. Amir Zarebkohan | Nanomedicine | Best Researcher Award

Tabriz University of Medical Sciences | Iran

Dr. Amir Zarebkohan’s research focuses on the development of advanced nanomedicine strategies for targeted drug delivery and cancer therapy. His work integrates medical nanotechnology and physiology to design innovative nanosystems capable of precise drug transport within biological environments. He specializes in smart targeted delivery platforms, nano–bio interface studies, and nano chemo-immunotherapy approaches aimed at improving therapeutic efficacy while minimizing systemic toxicity. His current projects involve the co-delivery of cyclophosphamide and HLH peptide using D8 and RIVAP-modified chitosan nanoparticles, engineered to respond to the redox conditions of the tumor microenvironment for glioma targeting in rat models. Additionally, he is developing chitosan-based nanoparticles containing dendrimers loaded with cyclophosphamide and sitagliptin, further functionalized with targeting ligands for enhanced delivery efficiency. His research emphasizes translational applications of nanotechnology in oncology and the exploration of biocompatible polymeric carriers for controlled and localized drug release. Through his studies, Dr. Zarebkohan contributes to advancing nano-chemoimmunotherapeutic platforms that bridge the gap between nanoscience and clinical medicine, offering potential breakthroughs in the treatment of complex and resistant cancers.

Profiles:  Google Scholar | Scopus | Orcid

Featured Publications:

Zarebkohan, A., & colleagues. (2024). Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model. Scientific Reports, 14, Article 75042.

Zarebkohan, A., & colleagues. (2024). Discovery of a novel dual targeting peptide for human glioma: From in-silico simulation to acting as targeting ligand. Advanced Pharmaceutical Bulletin, 14, Article 033.

Zarebkohan, A., & colleagues. (2023). Dual targeting salinomycin-loaded smart nano-micelles for enhanced accumulation and therapeutic outcome in breast cancer. International Journal of Pharmaceutics, 123095.

Zarebkohan, A., & colleagues. (2023). CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice. International Journal of Pharmaceutics, 122815.

Zarebkohan, A., & colleagues. (2023). Exosomal transmission of viruses, a two-edged biological sword. Cell Communication and Signalling, 21, Article 37.

Xin Li | Biomaterials | Best Researcher Award

Dr. Xin Li | Biomaterials | Best Researcher Award

Dr. Xin Li , The Chinese University of Hong Kong , Hong Kong

Dr. Xin Li is a dynamic and prolific researcher in the field of biomedical polymer materials and nanomedicine. With a Ph.D. from RWTH Aachen University under the mentorship of Prof. Andrij Pich, Dr. Li has carved a niche in responsive nanogels, ultrasound-triggered drug delivery, and smart biosensors. He currently holds a position as a Research Associate at The Chinese University of Hong Kong, following a postdoctoral fellowship at HKUST. Dr. Li has published over 70 SCI-indexed papers, earned 2600+ citations, holds 10 patents, and contributed to one academic book. His research stands out in top-tier journals like Nature Communications, Chem, Matter, and Advanced Materials. Recognized globally, he has led several high-impact research projects and received prestigious honors such as the 2024 JPA Prize and the 2021 Young Scientist Award. Dr. Li’s innovative mindset and cross-disciplinary expertise continue to push boundaries in biomedical engineering.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Outstanding Publication Record 📚
    Dr. Li has authored over 70 SCI-indexed publications in top-tier journals such as Nature Communications, Chem, Matter, Advanced Materials, and Angewandte Chemie. With an H-index of 32 and 2600+ citations, he demonstrates a strong impact in his field.

  2. Innovative and Translational Research 💡
    His work focuses on stimuli-responsive nanogels, mechanophore-based drug delivery, and biosensors, directly addressing real-world medical challenges like cancer therapy and infection monitoring.

  3. Leadership in International Projects 🌏
    Dr. Li has served as Principal Investigator and Co-leader of prestigious funding programs, including the Shanghai Overseas High-level Young Talent Program, Pujiang Program, and a Sino-German Research Grant, totaling over ¥1 million and €257,000.

  4. Interdisciplinary Expertise 🔬
    With a background in polymeric materials, biomedical engineering, and biophysics, he bridges the gap between material science and clinical applications, pushing the boundaries of modern nanomedicine.

  5. Recognized Honors and Editorial Roles 🏆
    Awards like the 2024 JPA Prize and the 2021 Young Scientist Award, along with his editorial contributions, highlight both his recognition and thought leadership in the scientific community.

⚠️ Areas for Improvement:

  1. Broader Industry Collaboration
    While Dr. Li has a strong academic and funding track record, increasing collaboration with biotech or pharmaceutical industries could further enhance the translational value of his research.

  2. Public Engagement and Science Communication
    As his work involves complex and novel biomedical technologies, more active engagement in science communication or public-facing platforms could broaden the reach and societal impact of his innovations.

  3. Diversified International Experience
    Though already globally active (Germany, China, Hong Kong), involvement in North American or broader EU collaborative networks might further strengthen his research diversity and global visibility.

🎓 Education:

Dr. Xin Li holds a Ph.D. in Biomedical Polymer Materials from RWTH Aachen University, Germany (2018–2023), where he worked under Prof. Andrij Pich, focusing on functional nanogels and stimuli-responsive systems for precise therapy. Prior to this, he earned an M.S. in Biomedical Engineering from Donghua University (2014–2017), supervised by Prof. Xiangyang Shi, with work centered around nanomaterials for gene and drug delivery. His academic journey began with a B.E. in Polymeric Materials and Engineering from Zhejiang A & F University (2010–2014), mentored by Prof. Pingan Song and Prof. Liang Chen. Across each academic stage, Dr. Li demonstrated an impressive aptitude for interdisciplinary innovation, combining materials science, chemical engineering, and biomedical applications. His strong educational foundation set the stage for his successful research career in developing next-generation nanomedicines and imaging technologies.

💼 Experience:

Dr. Xin Li currently serves as a Research Associate at The Chinese University of Hong Kong (2024–present), advancing cutting-edge research in nanomedicine. Prior to this, he was a Postdoctoral Fellow at The Hong Kong University of Science and Technology (2023–2024), where he expanded his expertise in responsive nanomaterials. His earlier research assistant roles at the DWI-Leibniz Institute (2022–2023) and Donghua University (2017) enriched his multidisciplinary experience. During his doctoral training at RWTH Aachen, Dr. Li led multiple collaborations and mentored students, reflecting his leadership potential. He has independently secured and led major grants like the Shanghai Overseas High-level Young Talent Program and the Pujiang Program. Dr. Li’s professional trajectory demonstrates a steady rise marked by impactful research, international collaboration, and continuous innovation in materials for imaging, therapy, and diagnostics.

🏅 Awards and Honors:

Dr. Xin Li has been consistently recognized for his contributions to biomedical engineering and nanomedicine. In 2024, he received the JPA Prize for his role as an Excellent Young Editorial Board Member. Earlier, in 2021, he was honored with the Young Scientist Award at the 3rd Global Experts Meeting on Chemistry and Medicinal Chemistry, acknowledging his innovative research in responsive drug delivery systems. He also earned the CSC-RWTH Scholarship in 2017, awarded by the China Scholarship Council for his doctoral studies in Germany, reflecting academic excellence and international research promise. In addition to these accolades, he has been entrusted with leadership roles in competitive grant programs such as the Shanghai Overseas High-level Talent Plan and the Sino-German Center collaborative research grant. These honors highlight Dr. Li’s status as an emerging leader in translational nanomedicine and interdisciplinary biomedical research.

🔬 Research Focus:

Dr. Xin Li’s research focuses on the design and development of stimuli-responsive nanogels, ultrasound-activated drug delivery systems, and smart biosensors. He is particularly interested in leveraging physical triggers (e.g., ultrasound, radiotherapy) to enable precise drug activation, offering high specificity and minimal side effects. His work on polymer mechanochemistry and hydrogel-based biosensors has opened new frontiers in non-invasive cancer therapy, infection monitoring, and imaging. With a deep understanding of polymer physics, biomedical engineering, and nanotechnology, Dr. Li integrates multiple disciplines to tackle challenges in tumor-targeted delivery, photothermal therapy, and metabolic reprogramming. His future focus includes developing clinically translatable systems for real-time therapy monitoring, immune modulation, and personalized medicine. By combining fundamental research with practical applications, Dr. Li aims to revolutionize how diseases like cancer and infections are diagnosed and treated.

📚 Publications Top Notes:

  1. 🧬 Transvascular transport of nanocarriers for tumor delivery, Nat. Commun., 2024

  2. 🧠 Leukocyte-nanomedicine system for targeted delivery and precise theragnostics, Chem, 2022

  3. 🩹 A wireless and battery-free DNA hydrogel biosensor for wound infection monitoring, Matter, 2022

  4. 💊 Radiotherapy-triggered prodrug activation: A new era in precise chemotherapy, Med, 2022

  5. 🧪 Engineered living hydrogels for robust biocatalysis in pure organic solvents, Cell Rep. Phys. Sci., 2022

  6. ☢️ Radiotherapy activated systems for precise tumor treatment, Nat. Rev. Cancer, 2025

  7. 💧 Sprayed aqueous microdroplets for spontaneous synthesis of functional microgels, Angew. Chem. Int. Ed., 2025

  8. 🧬 Functional dendrimer nanogels for DNA delivery and gene therapy of tumors, Angew. Chem. Int. Ed., 2025

  9. 🔥 Global cold local photothermal-mediated synergistic metabolic antitumor immunity, Adv. Mater., 2025

  10. 📡 Network topology of nanogels regulates mechanophore activation for ultrasound-mediated therapy, Angew. Chem. Int. Ed., 2025

🧾 Conclusion:

Dr. Xin Li is highly suitable and deserving of the Best Researcher Award. His exceptional research output, innovative project leadership, and contributions to translational biomedical science place him among the leading young researchers globally. While there is room for expanding industry ties and global engagement, his trajectory, impact, and recognition already demonstrate excellence well above typical benchmarks. Dr. Li exemplifies the future of interdisciplinary research and is a valuable asset to the global scientific community.